Early access program (EAP)

An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.

What is an early access program (EAP)?

An EAP, also known as compassionate use or expanded access, is a mechanism that provides eligible patients with access to investigational medicines outside of clinical trials. These programs are typically used when no satisfactory alternatives exist and are governed by strict regulatory requirements.

Why are EAPs important in pharmaceutical development?

EAPs offer patients potential benefit while allowing companies to collect additional safety or real-world data. They also build goodwill with the clinical and patient community, support pre-launch engagement, and may inform future regulatory and access strategies. Managing EAPs effectively requires close coordination with Regulatory and Medical Affairs teams.

HelixAI
Analyze your landscape in seconds with an AI-enhanced knowledge management...
Discover HelixAI
VISFO
Consulting
Optimize your strategic decision-making
Collaborate seamlessly, solve key challenges with proven strategic frameworks, and unlock deeper insights through precision intelligence.
Discover Consulting

See it in action with an interactive demo

See how VISFO’s precision intelligence and collaborative approach ensures you have the right insights, at the right time, to make the best possible strategic decisions.
Dashboard mockupiPhone mockup